In brief: Retatrutide (LY3437943) is an investigational medicine developed by Eli Lilly. It activates GIP, GLP-1 and glucagon receptors in a single molecule. Clinical research is examining its benefits and risks; it is not an authorised UK treatment. Lilly's research overview explains its investigational status.

Sources checked: 30 October 2026. This article provides educational information, not medical advice or instructions for use.

How does retatrutide work?

Retatrutide is called a triple receptor agonist because it activates three hormone receptors:

  • GIP: involved in insulin secretion and metabolic signalling.
  • GLP-1: involved in appetite and blood glucose regulation.
  • Glucagon: involved in glucose and energy metabolism.

Combining these targets is the scientific rationale for studying retatrutide. A proposed mechanism alone does not establish clinical benefit, safety or suitability for a particular person.

What does the clinical evidence show?

A randomised, placebo-controlled Phase 2 study published in the New England Journal of Medicine in 2023 enrolled 338 adults and followed treatment for 48 weeks. Researchers measured changes in body weight and assessed safety. The study reported weight reductions and adverse effects, including gastrointestinal events and increases in heart rate. Read the original study abstract and publication details.

This is one study, not a complete account of the evidence. Larger Phase 3 research is part of the development programme. A trial result applies to its participants and study conditions; it does not validate products advertised online or establish regulatory approval.

Safety limitations and UK regulatory status

Retatrutide has not been authorised for use in the UK. The MHRA warns that products sold as retatrutide outside legitimate clinical trials may present serious health risks. Research-use labelling, packaging or a supplier's analytical report does not establish that a product is an authorised medicine.

Do not use this article to select a product or plan self-administration. People seeking treatment for weight management or diabetes should speak with a qualified healthcare professional about authorised options. Read the MHRA's warning about unauthorised retatrutide products.

For the meaning of “reta pen” and what pen labels can tell you, see our retatrutide pen guide.

How to read retatrutide research critically

  • Check the source: distinguish a peer-reviewed study, a trial registry entry and a company announcement.
  • Check the population: results in one study group may not apply to other people or conditions.
  • Read benefits and harms together: look for adverse events, withdrawals and follow-up duration alongside the main outcome.
  • Check the comparison: results against placebo do not establish superiority to every available treatment.
  • Separate evidence from approval: trial findings and medicines authorisation answer different questions.

Frequently asked questions

Is retatrutide the same as a GLP-1 medicine?

GLP-1 is one of its three receptor targets. Retatrutide also targets GIP and glucagon receptors; it is a distinct investigational molecule.

Does a positive trial mean it is approved?

No. Published findings do not replace regulatory assessment or establish the quality of separately supplied products.

Where can I check the evidence?

Start with the original publication, the study's registered record and official regulatory information. Check publication dates and whether later evidence changes the interpretation.

Primary research and official sources


Legal Disclaimer

Products offered through Ultra Peps are presented for legitimate laboratory and scientific research purposes, subject to applicable laws and regulations. They are not represented as licensed or approved products for human or veterinary use, including therapeutic, diagnostic, clinical, or medical applications.

By placing an order, customers acknowledge their responsibility to understand and comply with the following conditions.

For Research Use Only

Peptides and other research compounds are intended solely for permitted laboratory studies and scientific investigation by appropriately qualified individuals or authorised organisations.

Not for Human or Veterinary Use

These products are not foods, medicines, dietary supplements, or medical devices. They must not be consumed, self-administered, or used to diagnose, prevent, treat, or manage any medical condition in humans or animals.

Customer Responsibility

Purchasers are responsible for ensuring that the purchase, possession, storage, handling, and use of research materials comply with all applicable laws, regulations, institutional requirements, and relevant safety procedures.

Returns and Refunds

Returns and refunds are subject to Ultra Peps' published terms and conditions and all applicable legal requirements. Any restrictions on returns or refunds will not affect statutory rights that cannot lawfully be excluded.

Permitted Research Applications Only

Products must only be used for legitimate and legally permitted research purposes. Customers are responsible for appropriate handling, storage, and compliance with relevant safety protocols.

Ultra Peps does not endorse unauthorised use, improper handling, or applications outside the permitted scope of scientific research. Nothing in this disclaimer overrides applicable legal or regulatory obligations.

0
0
Your Basket
Your cart is emptyReturn to Shop